Chugai Pharmaceutical Co Ltd (TOKYO: 4519) announced its financial results for the first 9 months of fiscal year 2020 on Thursday.
Revenue for the first 9 months of the 2020 fiscal year was JPY576.5bn, compared with JPY508.9bn for the same period of 2019.
IFRS operating profit for the first 9 months of 2020 was JPY227.3bn, compared with JPY160.9bn for the same 2019 period. IFRS net income for the 9-month period was JPY162.4bn, compared with JPY117.4bn for the first 9 months of 2019.
Commenting on the last (3rd) quarter, Tatsuro Kosaka, Chugai's chairman and CEO, said, 'As in the second quarter, strong growth in exports and royalty revenue far outpaced the decline in domestic product sales, helping Chugai to maintain high growth in the third quarter. The launch of the first recycling antibody Enspryng(R) in Japan and the United States was a major milestone. In terms of research and development, in-house projects that will come after Enspryng are progressing well as crovalimab and SPYK04 have advanced to new development stages. We will continue pursuing innovation based on our unique strength in science and technology to satisfy unmet medical needs and increase corporate value continuously.'
(USD1=JPY105)
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients